Jason Glanz
Concepts (384)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 36 | 2025 | 400 | 7.910 |
Why?
| | Vaccination | 66 | 2025 | 1428 | 6.740 |
Why?
| | Drug Overdose | 19 | 2025 | 354 | 5.880 |
Why?
| | Immunization Schedule | 22 | 2025 | 202 | 5.570 |
Why?
| | Opioid-Related Disorders | 11 | 2023 | 532 | 3.560 |
Why?
| | Analgesics, Opioid | 23 | 2025 | 1039 | 3.500 |
Why?
| | Influenza Vaccines | 25 | 2024 | 531 | 2.910 |
Why?
| | Social Media | 6 | 2021 | 158 | 2.830 |
Why?
| | Influenza, Human | 18 | 2024 | 611 | 1.890 |
Why?
| | Parents | 12 | 2021 | 1412 | 1.760 |
Why?
| | Patient Acceptance of Health Care | 8 | 2024 | 842 | 1.750 |
Why?
| | Consumer Health Information | 4 | 2020 | 49 | 1.700 |
Why?
| | Infant | 60 | 2025 | 9392 | 1.690 |
Why?
| | Vaccines, Inactivated | 9 | 2020 | 67 | 1.370 |
Why?
| | Cohort Studies | 37 | 2024 | 5688 | 1.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 14 | 2021 | 1365 | 1.360 |
Why?
| | Vaccination Coverage | 9 | 2025 | 89 | 1.320 |
Why?
| | Naloxone | 8 | 2022 | 121 | 1.310 |
Why?
| | Child, Preschool | 54 | 2025 | 10952 | 1.270 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 8 | 2020 | 96 | 1.260 |
Why?
| | Aluminum | 3 | 2022 | 41 | 1.250 |
Why?
| | Adverse Drug Reaction Reporting Systems | 7 | 2022 | 77 | 1.180 |
Why?
| | Chronic Pain | 5 | 2025 | 271 | 1.180 |
Why?
| | Humans | 157 | 2025 | 136962 | 1.180 |
Why?
| | Mothers | 3 | 2020 | 758 | 1.170 |
Why?
| | Measles-Mumps-Rubella Vaccine | 9 | 2021 | 45 | 1.160 |
Why?
| | Safety | 5 | 2018 | 343 | 1.140 |
Why?
| | Pregnancy Complications, Infectious | 8 | 2024 | 392 | 1.140 |
Why?
| | Internet | 5 | 2020 | 678 | 1.090 |
Why?
| | Treatment Refusal | 6 | 2015 | 95 | 1.090 |
Why?
| | Models, Statistical | 6 | 2018 | 662 | 1.070 |
Why?
| | Bias | 6 | 2021 | 222 | 1.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2020 | 247 | 1.050 |
Why?
| | Biometry | 2 | 2018 | 68 | 0.980 |
Why?
| | Female | 97 | 2025 | 73001 | 0.960 |
Why?
| | Narcotic Antagonists | 5 | 2022 | 181 | 0.960 |
Why?
| | Rotavirus Vaccines | 4 | 2020 | 42 | 0.950 |
Why?
| | Whooping Cough | 5 | 2018 | 54 | 0.930 |
Why?
| | Male | 84 | 2025 | 67385 | 0.910 |
Why?
| | Patient Safety | 2 | 2020 | 313 | 0.850 |
Why?
| | Colorado | 17 | 2025 | 4542 | 0.840 |
Why?
| | United States | 55 | 2025 | 14945 | 0.840 |
Why?
| | Chickenpox Vaccine | 6 | 2021 | 73 | 0.820 |
Why?
| | Incidence | 19 | 2024 | 2793 | 0.820 |
Why?
| | Electronic Health Records | 12 | 2024 | 1087 | 0.810 |
Why?
| | Retrospective Studies | 34 | 2024 | 15535 | 0.810 |
Why?
| | Patient Education as Topic | 4 | 2019 | 767 | 0.810 |
Why?
| | Case-Control Studies | 22 | 2020 | 3556 | 0.800 |
Why?
| | Measles | 3 | 2021 | 46 | 0.790 |
Why?
| | Pneumococcal Vaccines | 4 | 2025 | 134 | 0.770 |
Why?
| | Product Surveillance, Postmarketing | 8 | 2022 | 58 | 0.760 |
Why?
| | Pain Management | 1 | 2025 | 363 | 0.740 |
Why?
| | Statistics as Topic | 2 | 2013 | 297 | 0.740 |
Why?
| | Buprenorphine | 2 | 2022 | 176 | 0.730 |
Why?
| | Pharmacies | 1 | 2022 | 38 | 0.720 |
Why?
| | Pharmacoepidemiology | 1 | 2021 | 20 | 0.710 |
Why?
| | Vaccines, Attenuated | 4 | 2020 | 130 | 0.700 |
Why?
| | Child | 45 | 2022 | 21760 | 0.700 |
Why?
| | Adult | 49 | 2025 | 37713 | 0.680 |
Why?
| | Vaccination Refusal | 2 | 2019 | 69 | 0.680 |
Why?
| | Decision Making | 6 | 2019 | 935 | 0.670 |
Why?
| | Antigens | 2 | 2021 | 352 | 0.650 |
Why?
| | Antibodies, Viral | 1 | 2024 | 646 | 0.640 |
Why?
| | Disease Outbreaks | 4 | 2024 | 422 | 0.640 |
Why?
| | Risk Assessment | 13 | 2020 | 3446 | 0.630 |
Why?
| | Adolescent | 44 | 2025 | 21471 | 0.620 |
Why?
| | Reminder Systems | 1 | 2021 | 161 | 0.620 |
Why?
| | Text Messaging | 1 | 2021 | 161 | 0.590 |
Why?
| | Odds Ratio | 6 | 2019 | 1071 | 0.580 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2017 | 147 | 0.560 |
Why?
| | Morphine | 1 | 2019 | 158 | 0.560 |
Why?
| | Benzodiazepines | 1 | 2019 | 155 | 0.560 |
Why?
| | Communicable Diseases | 1 | 2020 | 161 | 0.550 |
Why?
| | Naltrexone | 1 | 2018 | 97 | 0.540 |
Why?
| | Databases, Factual | 4 | 2020 | 1367 | 0.540 |
Why?
| | Abortion, Spontaneous | 4 | 2021 | 104 | 0.540 |
Why?
| | Terminology as Topic | 1 | 2019 | 243 | 0.530 |
Why?
| | Middle Aged | 33 | 2025 | 33225 | 0.520 |
Why?
| | Databases, Pharmaceutical | 1 | 2016 | 6 | 0.500 |
Why?
| | Professional-Family Relations | 2 | 2015 | 151 | 0.480 |
Why?
| | Patient Compliance | 2 | 2019 | 591 | 0.470 |
Why?
| | Information Dissemination | 1 | 2017 | 221 | 0.470 |
Why?
| | Gastrointestinal Diseases | 2 | 2018 | 207 | 0.470 |
Why?
| | Managed Care Programs | 2 | 2013 | 141 | 0.460 |
Why?
| | Prescription Drug Diversion | 1 | 2015 | 12 | 0.460 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1251 | 0.450 |
Why?
| | Pregnancy | 17 | 2024 | 6736 | 0.440 |
Why?
| | Adjuvants, Immunologic | 1 | 2015 | 229 | 0.430 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2021 | 3661 | 0.430 |
Why?
| | Selection Bias | 1 | 2013 | 37 | 0.420 |
Why?
| | Infant, Newborn | 16 | 2025 | 6051 | 0.420 |
Why?
| | Housing | 1 | 2015 | 144 | 0.420 |
Why?
| | Sentinel Surveillance | 1 | 2013 | 48 | 0.420 |
Why?
| | Haemophilus Vaccines | 2 | 2025 | 29 | 0.400 |
Why?
| | Young Adult | 26 | 2025 | 13218 | 0.400 |
Why?
| | Confidence Intervals | 5 | 2021 | 331 | 0.390 |
Why?
| | Public Health Surveillance | 4 | 2021 | 84 | 0.390 |
Why?
| | Myocarditis | 3 | 2022 | 98 | 0.390 |
Why?
| | Reproducibility of Results | 5 | 2020 | 3266 | 0.390 |
Why?
| | Logistic Models | 7 | 2020 | 2066 | 0.380 |
Why?
| | Biostatistics | 1 | 2012 | 18 | 0.380 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 2 | 2012 | 15 | 0.370 |
Why?
| | Risk Factors | 16 | 2020 | 10363 | 0.370 |
Why?
| | Health Services | 1 | 2013 | 105 | 0.370 |
Why?
| | Environmental Exposure | 2 | 2015 | 573 | 0.370 |
Why?
| | Trust | 1 | 2013 | 142 | 0.370 |
Why?
| | Algorithms | 3 | 2018 | 1699 | 0.360 |
Why?
| | Practice Patterns, Physicians' | 6 | 2025 | 1295 | 0.360 |
Why?
| | Health Education | 1 | 2014 | 357 | 0.350 |
Why?
| | Epidemiologic Research Design | 1 | 2010 | 29 | 0.340 |
Why?
| | Hospitalization | 7 | 2020 | 2181 | 0.330 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2010 | 47 | 0.330 |
Why?
| | Aged | 18 | 2025 | 23803 | 0.330 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 3 | 2018 | 27 | 0.330 |
Why?
| | Prescriptions | 2 | 2020 | 69 | 0.330 |
Why?
| | Eczema | 2 | 2022 | 67 | 0.320 |
Why?
| | Asthma | 2 | 2022 | 1873 | 0.320 |
Why?
| | Pertussis Vaccine | 1 | 2009 | 24 | 0.310 |
Why?
| | Withholding Treatment | 2 | 2020 | 78 | 0.310 |
Why?
| | Immunization | 4 | 2024 | 404 | 0.300 |
Why?
| | Seizures | 4 | 2018 | 427 | 0.300 |
Why?
| | Chickenpox | 1 | 2010 | 81 | 0.300 |
Why?
| | Risk | 11 | 2021 | 901 | 0.300 |
Why?
| | Seasons | 7 | 2024 | 541 | 0.290 |
Why?
| | Surveys and Questionnaires | 9 | 2024 | 5812 | 0.290 |
Why?
| | Models, Theoretical | 4 | 2020 | 581 | 0.290 |
Why?
| | Immunization Programs | 5 | 2024 | 217 | 0.290 |
Why?
| | Predictive Value of Tests | 3 | 2021 | 1999 | 0.280 |
Why?
| | Clinical Trials as Topic | 2 | 2024 | 1019 | 0.280 |
Why?
| | Poisson Distribution | 4 | 2018 | 76 | 0.280 |
Why?
| | Focus Groups | 3 | 2015 | 535 | 0.270 |
Why?
| | Seizures, Febrile | 3 | 2018 | 21 | 0.270 |
Why?
| | Epidemiologic Methods | 3 | 2019 | 94 | 0.270 |
Why?
| | Mortality | 3 | 2021 | 356 | 0.270 |
Why?
| | Population Surveillance | 6 | 2013 | 487 | 0.260 |
Why?
| | Database Management Systems | 2 | 2020 | 51 | 0.260 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 1923 | 0.250 |
Why?
| | Thrombocytopenia | 2 | 2022 | 197 | 0.250 |
Why?
| | Time Factors | 10 | 2021 | 6786 | 0.250 |
Why?
| | Cross-Sectional Studies | 9 | 2025 | 5530 | 0.250 |
Why?
| | Haemophilus influenzae type b | 1 | 2025 | 12 | 0.240 |
Why?
| | Research Design | 5 | 2024 | 1114 | 0.230 |
Why?
| | Age Factors | 7 | 2020 | 3258 | 0.230 |
Why?
| | Haemophilus Infections | 1 | 2025 | 40 | 0.230 |
Why?
| | Transportation | 1 | 2025 | 53 | 0.220 |
Why?
| | Substance-Related Disorders | 4 | 2020 | 1058 | 0.220 |
Why?
| | Computer Simulation | 4 | 2013 | 982 | 0.220 |
Why?
| | California | 2 | 2024 | 437 | 0.220 |
Why?
| | Heroin Dependence | 2 | 2020 | 32 | 0.220 |
Why?
| | Fentanyl | 1 | 2025 | 97 | 0.220 |
Why?
| | Pneumococcal Infections | 1 | 2025 | 109 | 0.220 |
Why?
| | Pandemics | 5 | 2024 | 1630 | 0.210 |
Why?
| | Stillbirth | 2 | 2021 | 72 | 0.200 |
Why?
| | Opiate Substitution Treatment | 2 | 2022 | 155 | 0.200 |
Why?
| | Immunity, Humoral | 1 | 2024 | 117 | 0.200 |
Why?
| | Alcohol-Related Disorders | 1 | 2024 | 120 | 0.200 |
Why?
| | Health Services Research | 1 | 2006 | 406 | 0.200 |
Why?
| | Qualitative Research | 4 | 2020 | 1428 | 0.200 |
Why?
| | Intussusception | 2 | 2014 | 26 | 0.200 |
Why?
| | Smallpox Vaccine | 1 | 2022 | 23 | 0.200 |
Why?
| | Morphine Derivatives | 1 | 2022 | 17 | 0.200 |
Why?
| | World Health Organization | 2 | 2002 | 124 | 0.190 |
Why?
| | Pericarditis | 1 | 2022 | 10 | 0.190 |
Why?
| | Gestational Age | 3 | 2021 | 902 | 0.190 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1484 | 0.190 |
Why?
| | Alcoholism | 4 | 2012 | 796 | 0.190 |
Why?
| | Cataplexy | 1 | 2022 | 6 | 0.190 |
Why?
| | Bell Palsy | 1 | 2022 | 9 | 0.190 |
Why?
| | Anaphylaxis | 3 | 2021 | 104 | 0.190 |
Why?
| | Narcolepsy | 1 | 2022 | 21 | 0.190 |
Why?
| | Guillain-Barre Syndrome | 1 | 2022 | 22 | 0.190 |
Why?
| | Drug Prescriptions | 2 | 2015 | 258 | 0.180 |
Why?
| | Insurance | 1 | 2022 | 14 | 0.180 |
Why?
| | Delivery of Health Care, Integrated | 3 | 2021 | 281 | 0.180 |
Why?
| | Urban Population | 1 | 2025 | 481 | 0.180 |
Why?
| | Herpes Zoster Vaccine | 1 | 2024 | 154 | 0.180 |
Why?
| | Maternal Age | 1 | 2021 | 127 | 0.180 |
Why?
| | Premature Birth | 2 | 2024 | 334 | 0.180 |
Why?
| | Calibration | 1 | 2021 | 145 | 0.170 |
Why?
| | International Classification of Diseases | 2 | 2019 | 136 | 0.170 |
Why?
| | Health Behavior | 2 | 2019 | 780 | 0.170 |
Why?
| | Medical Informatics | 2 | 2019 | 100 | 0.170 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 357 | 0.170 |
Why?
| | Observational Studies as Topic | 2 | 2018 | 119 | 0.170 |
Why?
| | Heroin | 1 | 2020 | 31 | 0.160 |
Why?
| | Rural Population | 1 | 2025 | 582 | 0.160 |
Why?
| | RNA, Viral | 1 | 2024 | 682 | 0.160 |
Why?
| | Herpes Zoster | 1 | 2024 | 313 | 0.160 |
Why?
| | London | 1 | 2020 | 47 | 0.160 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 22 | 0.150 |
Why?
| | Bacterial Vaccines | 2 | 2023 | 63 | 0.150 |
Why?
| | Pharmacists | 1 | 2022 | 262 | 0.150 |
Why?
| | Term Birth | 1 | 2018 | 23 | 0.150 |
Why?
| | Insurance, Health | 1 | 2021 | 287 | 0.150 |
Why?
| | Diphtheria-Tetanus Vaccine | 1 | 2018 | 4 | 0.150 |
Why?
| | Alcohol Drinking | 2 | 2002 | 813 | 0.150 |
Why?
| | Birth Weight | 1 | 2021 | 508 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2020 | 225 | 0.140 |
Why?
| | Croup | 1 | 2018 | 19 | 0.140 |
Why?
| | Vaccines, Synthetic | 3 | 2024 | 126 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2020 | 347 | 0.140 |
Why?
| | Anemia, Sickle Cell | 2 | 2011 | 266 | 0.140 |
Why?
| | Monte Carlo Method | 1 | 2018 | 141 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5048 | 0.140 |
Why?
| | Cause of Death | 3 | 2018 | 428 | 0.140 |
Why?
| | Delayed-Action Preparations | 1 | 2018 | 173 | 0.140 |
Why?
| | Rhinitis, Allergic | 1 | 2018 | 41 | 0.140 |
Why?
| | Primary Health Care | 3 | 2018 | 1775 | 0.140 |
Why?
| | Diphtheria | 2 | 2018 | 21 | 0.130 |
Why?
| | Syncope | 1 | 2017 | 52 | 0.130 |
Why?
| | Tetanus | 2 | 2018 | 26 | 0.130 |
Why?
| | Measles Vaccine | 1 | 2017 | 21 | 0.130 |
Why?
| | Infant Mortality | 1 | 2018 | 114 | 0.130 |
Why?
| | Aged, 80 and over | 7 | 2018 | 7559 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2023 | 661 | 0.130 |
Why?
| | Papillomavirus Vaccines | 1 | 2021 | 317 | 0.130 |
Why?
| | Sex Factors | 2 | 2021 | 2060 | 0.130 |
Why?
| | Drug Hypersensitivity | 1 | 2017 | 91 | 0.120 |
Why?
| | Motivation | 1 | 2021 | 583 | 0.120 |
Why?
| | Immunization, Secondary | 3 | 2014 | 87 | 0.120 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 376 | 0.120 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 749 | 0.120 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2017 | 185 | 0.120 |
Why?
| | Attitude to Health | 1 | 2019 | 452 | 0.120 |
Why?
| | Parenting | 1 | 2019 | 315 | 0.120 |
Why?
| | Otitis Media | 1 | 2018 | 166 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 367 | 0.120 |
Why?
| | Fever | 1 | 2017 | 304 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 513 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 365 | 0.120 |
Why?
| | Prognosis | 2 | 2018 | 3931 | 0.120 |
Why?
| | Analysis of Variance | 4 | 2008 | 1301 | 0.120 |
Why?
| | Food Hypersensitivity | 1 | 2018 | 182 | 0.110 |
Why?
| | Age Distribution | 3 | 2017 | 388 | 0.110 |
Why?
| | Sex Distribution | 3 | 2017 | 373 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1730 | 0.110 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2013 | 13 | 0.110 |
Why?
| | General Practice | 1 | 2015 | 30 | 0.110 |
Why?
| | Telemedicine | 1 | 2024 | 863 | 0.110 |
Why?
| | Chronic Disease | 2 | 2013 | 1774 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2015 | 0.110 |
Why?
| | Needle Sharing | 2 | 2005 | 10 | 0.110 |
Why?
| | Infant, Premature | 1 | 2018 | 572 | 0.110 |
Why?
| | Breast Feeding | 1 | 2018 | 433 | 0.110 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2014 | 28 | 0.110 |
Why?
| | Acute Disease | 2 | 2008 | 993 | 0.110 |
Why?
| | User-Computer Interface | 1 | 2014 | 160 | 0.100 |
Why?
| | Respiratory Tract Infections | 1 | 2018 | 384 | 0.100 |
Why?
| | Mass Vaccination | 1 | 2013 | 18 | 0.100 |
Why?
| | Bacterial Capsules | 2 | 2025 | 30 | 0.100 |
Why?
| | Prehypertension | 1 | 2013 | 28 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 314 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 224 | 0.100 |
Why?
| | Ambulatory Care | 2 | 2018 | 567 | 0.100 |
Why?
| | Socioeconomic Factors | 4 | 2019 | 1310 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1459 | 0.100 |
Why?
| | Physicians, Primary Care | 1 | 2015 | 225 | 0.100 |
Why?
| | Drug Utilization | 1 | 2013 | 169 | 0.100 |
Why?
| | Genes, MHC Class II | 1 | 2012 | 75 | 0.100 |
Why?
| | Prisoners | 1 | 2015 | 150 | 0.100 |
Why?
| | Viral Vaccines | 1 | 2014 | 107 | 0.100 |
Why?
| | HIV Infections | 2 | 2024 | 2898 | 0.100 |
Why?
| | Substance Abuse, Intravenous | 2 | 2005 | 116 | 0.100 |
Why?
| | Program Development | 1 | 2014 | 367 | 0.100 |
Why?
| | Pneumonia | 1 | 2017 | 633 | 0.090 |
Why?
| | Community Health Centers | 1 | 2012 | 63 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2017 | 836 | 0.090 |
Why?
| | Comparative Effectiveness Research | 1 | 2012 | 153 | 0.090 |
Why?
| | Prescription Drugs | 1 | 2013 | 114 | 0.090 |
Why?
| | Vaccines, Combined | 3 | 2018 | 47 | 0.090 |
Why?
| | Evidence-Based Medicine | 1 | 2015 | 734 | 0.090 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 1154 | 0.090 |
Why?
| | Prisons | 1 | 2012 | 86 | 0.090 |
Why?
| | Hepatitis C | 2 | 2005 | 272 | 0.090 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 324 | 0.080 |
Why?
| | Anemia, Hemolytic | 1 | 2009 | 20 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 44 | 0.080 |
Why?
| | Communication | 1 | 2015 | 911 | 0.080 |
Why?
| | Autistic Disorder | 1 | 2011 | 205 | 0.070 |
Why?
| | Self Report | 2 | 2024 | 836 | 0.070 |
Why?
| | Drug Evaluation | 1 | 2008 | 80 | 0.070 |
Why?
| | Purpura, Thrombocytopenic | 1 | 2008 | 4 | 0.070 |
Why?
| | Platelet Count | 1 | 2008 | 85 | 0.070 |
Why?
| | Clinical Competence | 1 | 2015 | 1114 | 0.070 |
Why?
| | Splenectomy | 1 | 2008 | 61 | 0.070 |
Why?
| | Guideline Adherence | 1 | 2012 | 550 | 0.070 |
Why?
| | Communicable Disease Control | 1 | 2008 | 83 | 0.070 |
Why?
| | Linear Models | 2 | 2008 | 857 | 0.070 |
Why?
| | Health Surveys | 1 | 2009 | 523 | 0.070 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 305 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2012 | 757 | 0.060 |
Why?
| | Blood Pressure | 1 | 2013 | 1786 | 0.060 |
Why?
| | Prospective Studies | 4 | 2024 | 7512 | 0.060 |
Why?
| | Regression Analysis | 4 | 2015 | 1007 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 339 | 0.060 |
Why?
| | Mass Screening | 1 | 2013 | 1295 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1278 | 0.060 |
Why?
| | Hepatitis B | 1 | 2005 | 68 | 0.050 |
Why?
| | Hypertension | 1 | 2013 | 1299 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2025 | 167 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2807 | 0.050 |
Why?
| | Registries | 2 | 2008 | 2048 | 0.050 |
Why?
| | Monoamine Oxidase | 1 | 2002 | 28 | 0.050 |
Why?
| | Adenylyl Cyclases | 1 | 2002 | 63 | 0.050 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 416 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 191 | 0.050 |
Why?
| | Genetic Markers | 1 | 2002 | 346 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 521 | 0.040 |
Why?
| | Aftercare | 1 | 2023 | 208 | 0.040 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 2001 | 25 | 0.040 |
Why?
| | Radon | 1 | 2001 | 37 | 0.040 |
Why?
| | Cooperative Behavior | 2 | 2014 | 456 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 329 | 0.040 |
Why?
| | Disease Progression | 1 | 2008 | 2708 | 0.040 |
Why?
| | Stroke | 1 | 2009 | 1124 | 0.040 |
Why?
| | Health Facilities | 1 | 2020 | 84 | 0.040 |
Why?
| | Intention | 1 | 2021 | 174 | 0.040 |
Why?
| | Data Mining | 1 | 2020 | 116 | 0.040 |
Why?
| | Policy | 1 | 2021 | 152 | 0.040 |
Why?
| | Health Personnel | 2 | 2015 | 729 | 0.040 |
Why?
| | Blood Platelets | 1 | 2002 | 418 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 213 | 0.040 |
Why?
| | Prevalence | 2 | 2021 | 2732 | 0.040 |
Why?
| | Cellulitis | 1 | 2018 | 52 | 0.040 |
Why?
| | Cranial Nerve Diseases | 1 | 2018 | 42 | 0.040 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 37 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2021 | 297 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 689 | 0.030 |
Why?
| | Paralysis | 1 | 2018 | 72 | 0.030 |
Why?
| | Extremities | 1 | 2018 | 130 | 0.030 |
Why?
| | Brain Diseases | 1 | 2018 | 144 | 0.030 |
Why?
| | Patient Discharge | 1 | 2023 | 901 | 0.030 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 180 | 0.030 |
Why?
| | Family Health | 1 | 2017 | 194 | 0.030 |
Why?
| | Psychometrics | 1 | 2019 | 721 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2017 | 186 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2851 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 230 | 0.030 |
Why?
| | Smoking | 1 | 2002 | 1609 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 957 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2788 | 0.030 |
Why?
| | Outpatients | 1 | 2018 | 405 | 0.030 |
Why?
| | Contraindications | 1 | 2014 | 88 | 0.030 |
Why?
| | Fetal Mortality | 1 | 2013 | 3 | 0.030 |
Why?
| | Vaccines, Acellular | 1 | 2012 | 3 | 0.030 |
Why?
| | Vaccines, Conjugate | 1 | 2013 | 64 | 0.020 |
Why?
| | Fetal Death | 1 | 2013 | 57 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1626 | 0.020 |
Why?
| | Off-Label Use | 1 | 2012 | 53 | 0.020 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2013 | 91 | 0.020 |
Why?
| | Hepatitis A Vaccines | 1 | 2012 | 15 | 0.020 |
Why?
| | Rotavirus Infections | 1 | 2012 | 39 | 0.020 |
Why?
| | Monitoring, Immunologic | 1 | 2011 | 25 | 0.020 |
Why?
| | Safety Management | 1 | 2011 | 121 | 0.020 |
Why?
| | Mutation | 1 | 2001 | 3975 | 0.020 |
Why?
| | Ultrasonography | 1 | 2013 | 761 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 629 | 0.020 |
Why?
| | Family | 1 | 2012 | 670 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 2013 | 556 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2015 | 994 | 0.020 |
Why?
| | Patient-Centered Care | 1 | 2012 | 540 | 0.020 |
Why?
| | Neoplasms | 1 | 2001 | 2698 | 0.010 |
Why?
| | Mental Health | 1 | 2012 | 733 | 0.010 |
Why?
| | Syringes | 1 | 2005 | 43 | 0.010 |
Why?
| | Amphetamine-Related Disorders | 1 | 2005 | 40 | 0.010 |
Why?
| | Suicide | 1 | 2012 | 660 | 0.010 |
Why?
| | Health Maintenance Organizations | 1 | 2004 | 118 | 0.010 |
Why?
| | Methamphetamine | 1 | 2005 | 65 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2371 | 0.010 |
Why?
| | Social Identification | 1 | 2005 | 67 | 0.010 |
Why?
| | Medical Record Linkage | 1 | 2004 | 66 | 0.010 |
Why?
| | Cocaine-Related Disorders | 1 | 2005 | 111 | 0.010 |
Why?
| | Illinois | 1 | 2003 | 43 | 0.010 |
Why?
| | Social Environment | 1 | 2005 | 292 | 0.010 |
Why?
| | Affinity Labels | 1 | 2002 | 24 | 0.010 |
Why?
| | Equipment Contamination | 1 | 2003 | 67 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2004 | 547 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 420 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 815 | 0.010 |
Why?
| | Causality | 1 | 2001 | 127 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2012 | 2080 | 0.010 |
Why?
| | Biomarkers | 2 | 2002 | 4095 | 0.010 |
Why?
| | Marijuana Abuse | 1 | 2002 | 224 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 2223 | 0.010 |
Why?
|
|
Glanz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|